August 9, 2017

Mutation in prostate tumours shown to change epigenetic identity, the make-up of DNA

Prostate cancer researchers have mapped the impact of an acquired mutation that alters epigenetic identity, the make-up of DNA, in about 50 per cent of patient tumour samples. The discovery also identifies a new opportunity for targeted therapy.

Continue reading – Mutation in prostate tumours shown to change epigenetic identity, the make-up of DNA

March 16, 2017

Researchers discover new test that could change the diagnosis and treatment of prostate cancer

Dr. Paul Boutros

Genetic tests are being used more commonly in the diagnosis of many types of cancer. However, there currently isn’t a highly accurate test that can identify men with aggressive forms of prostate cancer, making it more difficult to choose the most appropriate course of treatment.

Continue reading – Researchers discover new test that could change the diagnosis and treatment of prostate cancer

January 10, 2017

New prognostic test for prostate cancer now closer to clinical use

Dr. Emilie Lalonde

Prostate cancer is the most common cancer in Canadian men, but there is still no one-size-fits-all strategy for treating the disease. Currently it is difficult to choose exactly the right type and amount of treatment for each individual because it is hard to accurately assess how aggressive the cancer is. Researchers are now a step closer to bringing a powerful new prognostic tool into clinical use.

Continue reading – New prognostic test for prostate cancer now closer to clinical use

January 9, 2017

Pan-Canadian research team uncovers ‘signature’ to reduce overtreatment of prostate cancer

Dr. Paul Boutros

A team of researchers and clinician-scientists from across Canada have discovered a signature of 41 mutations that are common in prostate cancer and will help to prevent patients with non-aggressive disease from being overtreated. Dr. Paul Boutros, a Principal Investigator in OICR’s Informatics and Bio-computing Program and Co-Lead of the Canadian Prostate Cancer Genome Network (CPC-GENE), answered a few questions about how the signature was developed and its potential impact on patients.

Continue reading – Pan-Canadian research team uncovers ‘signature’ to reduce overtreatment of prostate cancer

January 9, 2017

Scientists identify DNA signature linked to prostate cancer severity

Findings published in renowned journal Nature

January 9, 2017 – TORONTO, ON – The Canadian Prostate Cancer Genome Network (CPC-GENE) has published findings from the world’s most comprehensive genetic analysis of prostate cancer tumours in the journal Nature. Led by Drs. Robert Bristow of the Princess Margaret Cancer Centre and Paul Boutros of the Ontario Institute for Cancer Research, CPC-GENE has uncovered the full set of mutations that can occur in the most common cancer in men. By fully cataloging these mutations, the CPC-GENE team was able to create a new signature that predicts at an early stage whether a prostate cancer tumour will become aggressive or not, allowing for personalized treatment.

Continue reading – Scientists identify DNA signature linked to prostate cancer severity

January 5, 2017

Researchers disprove link between vasectomies and prostate cancer using Ontario health data

Doctor holding a tick

Are vasectomies safe? Some recent studies have found a link between vasectomies and the development of prostate cancer later in life. But new research using Ontario health data has challenged these studies and shown conclusively that there is no link, giving new peace of mind to those men who have undergone or are considering undergoing the procedure.

Continue reading – Researchers disprove link between vasectomies and prostate cancer using Ontario health data

December 6, 2016

Congratulations to Ahmed Aman on another successful Movember fundraiser

Dr. Ahmed Aman poses for a photo in front of a window

Dr. Ahmed Aman, Principal Research Scientist and Group Leader, Analytical Chemistry and ADME in OICR’s Drug Discovery Program, recently demonstrated that his commitment to cancer research goes beyond his work in the lab. For the sixth straight year Aman participated in Movember by growing a moustache to raised funds and awareness for men’s health issues, including prostate cancer. This year Aman exceeded his fundraising goal of $500 by collecting $770 in donations and has now raised $3,445 since beginning in 2011.

More information about Movember can be found here: https://ca.movember.com/

November 9, 2016

The next generation: Tamara Jamaspishvili

Tamara Jamaspishvili

Men newly diagnosed with prostate cancer face a difficult dilemma: either wait and see how the growth develops and whether it is aggressive, or treat it fully right away and risk the many long-term side effects of treatment. Dr. Tamara Jamaspishvili is a young researcher at Queen’s University in Kingston who is working to change that.

Continue reading – The next generation: Tamara Jamaspishvili

October 19, 2016

From our Annual Report: Personalizing prostate cancer treatment

Dr. Emilie Lalonde

Prostate cancer is the most common cancer in Canadian men and while it has been the focus of extensive research, an estimated 4,000 Canadians die of the disease each year. That is why six years ago Dr. Paul Boutros and Dr. Rob Bristow set out to sequence the normal and diseased tissue of 350 patients and learn from a clinical perspective how genomic information can be used to guide better treatment.

Continue reading – From our Annual Report: Personalizing prostate cancer treatment

October 12, 2016

OICR’s Natalie Fox awarded Philip Feldberg Studentship by Prostate Cancer Canada

Natalie Fox and supporters

Prostate cancer is a complex disease. In a clinical setting it can be hard for doctors to accurately predict outcomes for prostate cancer patients, especially for those deemed to be at an intermediate risk of recurrence. With intermediate risk cancers, unlike those that are high or low risk, it is unclear how the cancer will develop. This makes it difficult to choose exactly the right therapy and avoid unnecessary treatments and their associated side effects.

Continue reading – OICR’s Natalie Fox awarded Philip Feldberg Studentship by Prostate Cancer Canada

September 15, 2016

Dr. Paul Boutros talks genomics and prostate cancer research

Dr. Paul Boutros, Principal Investigator in Informatics and Bio-computing at OICR, spoke to our partners at Prostate Cancer Canada/Movember Canada about the role of genomics and informatics in prostate cancer research. Boutros also spoke about the CPC-GENE project – the largest study of prostate cancer genomics in the world.

August 16, 2016

New research published on the role of noncoding RNA in prostate cancer

Dr. He

Noncoding RNA may play a bigger role in driving prostate cancer development and progression that previously thought. 

On Monday the University Health Network’s Princess Margaret Cancer Centre announced that prostate cancer researchers, funded in part by OICR, have pinpointed the key regulatory role of 45 noncoding genes in the development and progression of prostate cancer. The research was published in Nature Genetics.

Continue reading – New research published on the role of noncoding RNA in prostate cancer